$1.35
1.50% yesterday
Nasdaq, Jun 25, 10:00 pm CET
ISIN
US8342233074
Symbol
SNGX
Sector
Industry

Soligenix, Inc. Stock price

$1.35
-0.46 25.41% 1M
-1.51 52.80% 6M
-1.35 49.91% YTD
-1.30 49.06% 1Y
-131.45 98.98% 3Y
-451.80 99.70% 5Y
-574.07 99.77% 10Y
-75.37 98.24% 20Y
Nasdaq, Closing price Wed, Jun 25 2025
+0.02 1.50%
ISIN
US8342233074
Symbol
SNGX
Sector
Industry

Key metrics

Basic
Market capitalization
$4.4m
Enterprise Value
$-2.9m
Net debt
$-7.3m
Cash
$7.3m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 11.01
EV/Sales
- | 1.46
EV/FCF
0.32
P/B
1.19
Financial Health
Equity Ratio
45.93%
Return on Equity
-200.74%
ROCE
-293.77%
ROIC
-
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$0.0 | $800.0k
EBITDA
$-10.6m | -
EBIT
$-10.6m
Net Income
$-9.6m | $-16.6m
Free Cash Flow
$-8.9m
Growth (TTM | estimate)
Revenue
-100.00% | 566.67%
EBITDA
-32.05% | -
EBIT
-32.02%
Net Income
-36.80% | -100.24%
Free Cash Flow
-14.52%
Margin (TTM | estimate)
Gross
0.00%
EBITDA
-462,156.52% | -
EBIT
-462,365.22%
Net
-416,869.57% | -2,070.00%
Free Cash Flow
-387,313.04%
More
EPS
$-3.14
FCF per Share
$-2.80
Short interest
1.23%
Employees
15.00
Rev per Employee
$10.00k
Show more

Is Soligenix, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Soligenix, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Soligenix, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Soligenix, Inc.:

Buy
100%

Financial data from Soligenix, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.28 4.28
0% 0%
-
- Research and Development Expense 6.36 6.36
84% 84%
-
-11 -11
32% 32%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
32% 32%
-
Net Profit -9.59 -9.59
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about Soligenix, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Soligenix, Inc. Stock News

Neutral
GlobeNewsWire
20 days ago
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies...
Neutral
PRNewsWire
about 2 months ago
PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025.
Neutral
PRNewsWire
2 months ago
Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from...
More Soligenix, Inc. News

Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Head office United States
CEO Christopher Schaber
Employees 15
Founded 1987
Website www.soligenix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today